Skip to content

Citations

  1. Based on a double-blind, third-party 12 week clinical study with 22 participants aged 54-64. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024.)
  2. Based on ex vivo and in vitro lab studies measuring levels of senescence and senescence-associated biomarkers (CDKN2A/P16, CDKN1A/P21, H2A.J, CXCL8 and IL-6) which indicate reduction in senescence (Zonari, A., et al. npj Aging, 2023). Lab findings may not reflect outcomes in human use and do not represent whole-body aging or medical claims.

[Regulatory disclaimer. Partner disclosure: Dave Asprey is a paid OneSkin partner, if applicable.]